Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
Adaptor Proteins, Signal Transducing
/ antagonists & inhibitors
Animals
Antibodies, Neutralizing
/ therapeutic use
Bone and Bones
/ pathology
Collagen Type I
/ genetics
Disease Models, Animal
Extracellular Matrix Proteins
/ genetics
Female
Fractures, Bone
/ prevention & control
Male
Mice
Mice, Knockout
Molecular Chaperones
/ genetics
Osteogenesis Imperfecta
/ drug therapy
Phenotype
Random Allocation
X-Ray Microtomography
Fractures
Osteogenesis imperfecta
Sclerostin antibody
Vertebrae
oim/oim
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
27
07
2019
accepted:
28
12
2019
pubmed:
7
2
2020
medline:
15
7
2021
entrez:
7
2
2020
Statut:
ppublish
Résumé
In osteogenesis imperfecta (OI), vertebrae brittleness causes thorax deformations and leads to cardiopulmonary failure. As sclerostin-neutralizing antibodies increase bone mass and strength in animal models of osteoporosis, their administration in two murine models of severe OI enhanced the strength of vertebrae in growing female Crtap
Identifiants
pubmed: 32025752
doi: 10.1007/s00223-019-00655-5
pii: 10.1007/s00223-019-00655-5
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Antibodies, Neutralizing
0
Col1a2 protein, mouse
0
Collagen Type I
0
Crtap protein, mouse
0
Extracellular Matrix Proteins
0
Molecular Chaperones
0
Sost protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM